Pollara, Justin
Khanal, Santosh
Edwards, R. Whitney
Hora, Bhavna
Ferrari, Guido
Haynes, Barton F.
Bradley, Todd
Funding for this research was provided by:
National Institutes of Health (UM1-AI100645, R01-AI147778)
Article History
Received: 2 June 2022
Accepted: 21 September 2022
First Online: 29 September 2022
Declarations
:
: Deidentified peripheral blood mononuclear cell (PBMC) samples were used from existing cohorts of HIV-1-infected and seronegative individuals stored at the Duke Human Vaccine Institute that were approved by the Duke Medicine Institutional Review Boards as well as the ethics boards of the local sites (Duke IRB Pro00039127 and Pro00007562). Participants were originally enrolled in the study and written informed consent was obtained from all subjects and/or their legal guardian(s). All methods were carried out in accordance with the relevant guidelines and regulations of the Duke Medicine Institutional Review Boards as well as the ethics boards of the local sites in accordance with the Declaration of Helsinki. All experimental protocols reported in this manuscript with the human samples were reviewed and approved by the Duke institutional review board.
: Not applicable.
: The authors declare no competing interests.